Run it like an honest experiment: three grams a day, twice daily with food, for eight to twelve weeks before you judge. The catch is the wait — most people quit at week two, before any of the trials would have seen an effect. Joint pain is where it earns its keep; muscle soreness recovery is a useful bonus; the skin, hair, and nail story is plausible mechanism with thin trial data, so treat it as a fringe benefit, not the reason to start.
MSM is methylsulfonylmethane, a small molecule that's roughly a third sulfur by weight. Sulfur is the body's third most abundant mineral — the element that forms the disulfide bonds holding keratin together in your hair and nails, that cross-links collagen in skin and cartilage, that anchors the sulfated sugars in joint matrix, and that builds glutathione, the antioxidant your cells run on. You get sulfur from protein (methionine, cysteine), cruciferous vegetables, and onions and garlic. MSM is sulfur in a form your body can grab fast.
Two threads do the work in the human body, both modest. It dampens inflammatory signalling. In cells and animals, MSM quiets the NF-κB pathway and lowers the inflammatory cytokines TNF-α, IL-6, and IL-1β; in human trials it nudges C-reactive protein down a little Butawan et al. 2017. It tops up your antioxidant tank. By feeding sulfur into glutathione synthesis, it raises the level of your body's main intracellular antioxidant and lowers oxidative-stress markers under the kind of strain that hard exercise produces Withee et al. 2017. Neither mechanism rebuilds anything — MSM doesn't regrow cartilage and doesn't fix a torn meniscus. What it does is plausibly take the edge off the inflammatory and oxidative load your joints and muscles deal with, at a magnitude that matches what the trials actually show.
Does it actually work?
The clean answer: real but modest, mostly for knees. Five placebo-controlled trials in knee osteoarthritis all point the same way — pain down, function up, by roughly the magnitude of a low-dose anti-inflammatory, after eight to twelve weeks. None of those trials is large. There is no Cochrane-tier mega-trial, and no major orthopaedic guideline mentions MSM Bannuru et al. 2019. The consistent direction of small trials is the strongest claim the evidence supports; "MSM helps knee pain a bit" is what the data backs, and that is also where the writing of MSM proponents most often overshoots.
Outside knees, the evidence gets thinner fast. The best non-joint trial is on half-marathon runners taking three grams a day for three weeks before the race: less post-race muscle pain, lower TNF-α, trends toward reduced oxidative damage Withee et al. 2017. Useful if you train hard. Skin, hair, and nail trials exist but are small, mostly use combination products, and rely on subjective ratings — enough to say "plausible," not enough to say "shown" Berardesca et al. 2008. The systematic review by Brien et al. 2008 summarises the OA evidence the way you'd hope a careful researcher would: positive direction, methodologically limited trials, not definitive.
What you keep paying for if you ignore this
The stakes here aren't health-collapse stakes. They're aisle stakes. The version of you that doesn't run this experiment keeps wandering past the joint-supplement shelf and picking up the forty-dollar-a-month combination bottle that promises to rebuild cartilage. You drink it for two months, you can't tell if it's doing anything, you stop, you find another one, you try that. A year later you've spent four hundred dollars on stacks where MSM is one of several ingredients at sub-trial doses, you still don't know whether any of it helps you, and the morning knee complaint is still there on the second flight of stairs.
The other version — the one that takes the cheap audited-grade powder for twelve straight weeks at the dose the trials used — has an answer at the end. Either the stairs are noticeably easier (and at twenty dollars a year, you keep going), or they aren't (and you stop, and you've lost a coffee's worth of money learning that MSM specifically isn't your lever). Most of what the joint-supplement industry sells you is the year of not knowing; running the trial honestly is what gets you out of it.
How to actually take it
Three grams a day, split into two doses, for at least two months before you decide whether it's working. If you're tracking specifically for joint pain, give it the full twelve weeks — that's the trial window, and the effect builds gradually. For training recovery, two to three weeks of loading before a hard block is enough Withee et al. 2017. Take it with food or without; no meaningful difference. Powder dissolves in water with a faintly bitter aftertaste; capsules avoid the taste at a small price premium.
When to skip it or ask first
MSM has one of the cleanest safety profiles in the supplement world — the rat lethal dose is higher than table salt's, no serious adverse events have shown up in human trials at three to six grams a day for months, and the side effects that do appear are mild and uncommon: occasional nausea, loose stools, mild headache Butawan et al. 2017. For most readers, the honest answer is "you can try this without worrying."
What the marketing gets wrong
"MSM rebuilds cartilage." No human trial has shown structural change on imaging — what it does is take the edge off symptoms Brien et al. 2008. The bottle that promises to regenerate your knee is selling you something the data doesn't back.
"Most people are sulfur-deficient." The supplement-industry framing. The typical Western diet supplies around a gram of sulfur a day from protein and vegetables — enough for the body's structural needs. If you're a healthy adult eating any animal protein, eggs, or cruciferous vegetables, you're not deficient. The case for MSM isn't "fixing a deficiency"; it's "providing a small extra anti-inflammatory and antioxidant nudge."
"MSM and DMSO are the same." MSM is the stable metabolite of DMSO. Same sulfur, different molecule. MSM is odourless, solid, and lacks the tissue-penetrating solvent action that makes DMSO controversial.
"More is better." Trials at three and six grams a day show similar effects. Above six grams, gastrointestinal side effects climb without a corresponding benefit. Stay in the trial range.
The skin, hair, and nail question
The marketing for MSM leans hard on beauty claims, and this is where the catalogue has to be honest: the mechanism is real, the evidence is thin. Sulfur is genuinely what your body uses to build the disulfide bonds in keratin (hair shaft, nail plate) and to cross-link collagen in skin. Topping up the substrate is biologically reasonable. What the trial work actually shows is small, mostly combination-product, and mostly subjective — improvements in skin hydration and rosacea symptoms in a study that mixed MSM with silymarin Berardesca et al. 2008, and subjective self-reports of better hair and nail quality in an open-label trial of an MSM-containing oral formulation Butawan et al. 2017. No monotherapy trial with hair shaft strength, nail growth rate, or instrumented skin endpoints exists.
The honest framing: if you're starting MSM for knee pain or training recovery, the slight long-term contribution to your sulfur-built tissues is a bonus you can keep. If you're starting it specifically for thicker hair or stronger nails, you're betting on mechanism without trial backing, and that bet is more often won by collagen peptides, biotin if you're actually deficient, or solving the protein-intake problem upstream.
What else, and what doesn't replace
In the joint-supplement aisle, MSM's company is glucosamine + chondroitin (similar evidence quality, similar effect size, well-tolerated, stacks with MSM per Usha and Naidu 2004), curcumin extracts (similar small-RCT signal, more interaction-prone), omega-3 fish oil at two to three grams a day (broader systemic benefit, useful regardless), and collagen peptides at around ten grams a day (growing evidence for joint and skin endpoints). The stacking case for MSM is strongest with glucosamine; the case for picking one is strongest if cost matters and you want the lowest-friction trial.
None of these are the load-bearing intervention for joint pain. The OARSI guideline for knee and hip OA puts structured strengthening exercise, weight loss in overweight patients, and topical or oral NSAIDs for flares at the top of its recommendations Bannuru et al. 2019. If you're only running the supplement experiment and not the exercise one, you're optimising the smaller lever. Run both.
Why people say "I tried it and nothing happened"
Three reasons, in order of frequency. Quit too early. The trial benefit lands at eight to twelve weeks. At week two there isn't anything to feel yet — and that's the week most people stop. Mark a date twelve weeks out the day you start; don't judge before then. Under-dosed. The "joint health" labels on combination bottles often put MSM at five hundred milligrams per serving, well under the dose at which trials show effect. Three grams a day is the floor that matches the data. Wrong problem. MSM works for the symptomatic edge of inflammation in the joint or muscle. It does nothing for a torn meniscus, a labral tear, a herniated disc, or bone-on-bone end-stage osteoarthritis. If you've been told the joint needs imaging or surgery, no supplement is the answer.
And one quality issue: unbranded bulk MSM from unaudited suppliers can carry process residues. Spending fifteen instead of twenty dollars for the year saves five dollars and exposes you to a question the audited brands have already answered. Stick to OptiMSM or equivalent.
The real-world friction
Cost runs roughly fifteen to thirty dollars a year at three grams a day in bulk audited-grade powder from a major supplement retailer, slightly more for capsules. No prescription, no monitoring, no special timing. The powder dissolves in water — a small scoop, faint bitter taste, drinks fine in juice or a protein shake if you'd rather not taste it. Capsules at the trial dose mean two to four big pills a day; the powder is easier on the swallow but worse on the suitcase. Two-month supply is the smallest practical bag to buy; year-supply tubs cost no more per gram and remove the re-ordering tax.
Insurance doesn't cover it because it's not a medication, and you don't need anyone's permission to start. If you're already taking a joint supplement that includes MSM at three grams or more split through the day, you're effectively already running this experiment — check the label.
What changes if it works
It's a quiet payoff, not a transformation. Weeks one through four, nothing — you're showing up to the experiment without a result yet. Around week six the morning is slightly easier; you didn't notice the change happen, you just notice the absence of the usual flinch on the first step. By week eight to twelve the knee complaint that used to be a constant of the stairs is a thing you sometimes forget about, the pain score someone would have asked you to rate has dropped a couple of points, and the hard-training week you used to need an extra rest day after takes one fewer day to clear Kim et al. 2006 Withee et al. 2017.
What other people notice: not much. This is one of the entries where the payoff is internal — your own knees, your own recovery — rather than something a partner or a colleague comments on. The shelf in your bathroom has one bag of cheap powder where it used to have three bottles of promises. The line item in your monthly spend that used to read forty dollars now reads nothing. The version of you that runs the next twelve-week experiment — exercise, weight, omega-3, collagen — has one fewer unknown to carry into it.
Related
If MSM is part of your joint-pain stack, the bigger levers are sitting right next to it: structured strengthening exercise for the affected joint, weight management if that's a factor, omega-3 fatty acids for systemic inflammation, and collagen peptides if you're chasing the skin-and-hair payoff specifically. For the broader question of what actually works in knee osteoarthritis, the OARSI guideline is the rigorous summary. For exercise recovery beyond MSM, look at tart cherry juice, curcumin, and sleep — sleep does more for recovery than any supplement on this shelf.
Substance and claimed effects
Methylsulfonylmethane (MSM), also called dimethyl sulfone (chemical formula (CH3)2SO2), is a small, water-soluble organosulfur compound — a stable, oxidised metabolite of dimethyl sulfoxide (DMSO). It occurs naturally in trace amounts in plants, milk, and human plasma, and is industrially synthesised for supplements (typically as the purified raw material OptiMSM) Butawan et al. 2017. Marketed claims, in order of evidence depth: reduction of knee osteoarthritis pain and stiffness; reduction of post-exercise muscle soreness and oxidative stress; anti-inflammatory effect (CRP, IL-6, TNF-α reductions in small trials); support for skin, hair, and nail quality through sulfur donation to keratin, collagen, and glutathione synthesis; secondary claims around seasonal allergy symptoms. This entry covers each non-trivial claim — joint pain, inflammation, exercise recovery, and skin/hair/nails — and scores the meta dimensions holistically.
Evidence by addressing question
Mechanism
MSM is ~34% sulfur by mass. Sulfur is the third most abundant mineral in the body and is structurally required for the disulfide bonds that stabilise keratin (hair, nails), collagen cross-links (skin, cartilage), the sulfated glycosaminoglycans of cartilage matrix, and the tripeptide glutathione — the body's primary intracellular antioxidant Butawan et al. 2017. Orally administered MSM is rapidly and near-completely absorbed, distributes widely (including across the blood-brain barrier), and is excreted in urine with a plasma half-life of roughly 12 hours. Pharmacokinetic work in humans shows steady-state plasma sulfur availability with daily dosing at gram quantities Butawan et al. 2017.
Two mechanistic threads dominate. (1) Anti-inflammatory signalling. In cell and animal models, MSM suppresses NF-κB activation, downregulates inducible nitric oxide synthase (iNOS) and COX-2, and reduces pro-inflammatory cytokines IL-1β, IL-6, and TNF-α; in human trials it has lowered serum CRP and IL-6 modestly Butawan et al. 2017. (2) Antioxidant capacity. By contributing sulfur to glutathione synthesis and acting as a thiol-sparing molecule, MSM raises plasma glutathione availability and lowers markers of oxidative stress (malondialdehyde, protein carbonyls) under exercise stress Withee et al. 2017. Neither mechanism has been shown to reverse cartilage loss or cure inflammatory disease in humans; both can plausibly explain a symptomatic effect at the magnitude reported in clinical trials.
Evidence
Knee osteoarthritis. The strongest evidence base. Four small randomised, placebo-controlled trials converge on a modest, real effect: Kim et al. 2006 (n=50, 3 g twice daily for 12 weeks) found roughly a 25% reduction in pain VAS and 30% in WOMAC physical-function score versus placebo; Usha and Naidu 2004 (n=118, 500 mg three times daily) found ~30–35% pain reduction at 12 weeks, broadly comparable to glucosamine, with additive benefit from the combination; Debbi et al. 2011 (n=49, 6 g/day for 12 weeks) reported significant improvement in WOMAC pain and function. Lubis et al. 2017 tested MSM added to glucosamine-chondroitin and found WOMAC improvements but no significant edge over the dual product alone. Notarnicola et al. 2016 found MSM + boswellic acids non-inferior to glucosamine sulfate at 60 days. The Cochrane-style synthesis is Brien et al. 2008: "positive but not definitive" — small trials, methodological limits, but a consistent direction.
Exercise-induced muscle damage. Withee et al. 2017, a half-marathon-runner RCT (n=22, 3 g/day for 21 days pre-race), found reduced post-race muscle and joint pain, lower TNF-α, and trends toward reduced oxidative-stress markers. Earlier untrained-subject trials reported reduced delayed-onset muscle soreness after eccentric exercise at 1.5–3 g/day. Effect sizes are small to moderate; sample sizes are small.
Skin, hair, nails. The thinnest leg. Berardesca et al. 2008 showed improvement in rosacea symptoms (erythema, hydration, redness) with topical silymarin + MSM, but as a combination product, isolating MSM is impossible. A small open-label trial of an oral MSM-based formulation reported subjective improvement in skin hydration, hair shine, and nail strength over 4 months Butawan et al. 2017. No large RCTs isolating MSM for skin or hair endpoints exist.
Allergic rhinitis. A single industry-funded open-label trial (n=50, 2.6 g/day for 30 days) reported reduced upper-respiratory and nasal symptoms; no placebo control. Worth noting, not relied on Butawan et al. 2017.
What major OA guidelines say. The 2019 OARSI guideline for non-surgical knee/hip OA management does not include MSM among its conditionally or strongly recommended interventions Bannuru et al. 2019. The American College of Rheumatology and AAOS guidelines similarly do not endorse MSM. The asymmetry — small trials positive, guidelines silent — is the central evidence tension.
Protocol
Dosing in successful OA trials: 3–6 g/day, typically split twice daily, with or without food, run for at least 8–12 weeks before judging effect Kim et al. 2006 Debbi et al. 2011. The Usha and Naidu protocol of 500 mg three times daily reached significance at lower total dose (1.5 g) but went 12 weeks. For exercise recovery, 1.5–3 g/day, started at least 2–4 weeks before a target event, used through the recovery window Withee et al. 2017. The crystalline powder form (e.g., OptiMSM) is what trial work has used. Capsules are equivalent in bioavailability; powder is cheaper. No food-interaction concerns documented.
Contraindications and safety
The safety profile is exceptionally clean. Acute oral LD50 in rats exceeds 17 g/kg — less toxic than table salt. Subchronic and chronic toxicity studies at doses up to 1.5 g/kg/day in animals show no organ-specific toxicity. Human trials at 3–6 g/day for 12 weeks report mild gastrointestinal symptoms (nausea, diarrhoea, bloating, mild headache) at low frequency, no serious adverse events, and no significant changes in haematology, liver, or kidney panels Butawan et al. 2017. Doses up to 4 g/day for 26 weeks in humans have been tolerated.
Theoretical cautions: (1) Anti-platelet/anti-coagulant interactions are speculated based on sulfur chemistry but have no documented clinical signal; case-by-case discussion warranted for patients on warfarin or DOACs. (2) Pregnancy and breastfeeding lack adequate trial data; standard "insufficient data" caveat applies. (3) Hypersensitivity to sulfa drugs is mechanistically unrelated to MSM (different chemistry), but anecdotal reports of skin reactions exist.
Misconceptions
"MSM regrows cartilage." It does not — no human trial has shown structural disease modification on MRI or X-ray; the demonstrated effect is symptomatic Brien et al. 2008. "Most people are sulfur-deficient." Plausible only in very low-protein diets; the typical Western diet supplies 0.5–1.5 g/day of sulfur from methionine and cysteine in animal protein, cruciferous vegetables, and alliums. "MSM is the same as DMSO." It is the metabolite — same sulfur, but MSM is solid, odourless, and lacks DMSO's tissue-penetrating solvent properties. "Sulfa allergy means avoid MSM." Sulfa drugs are sulfonamide-based; MSM is a sulfone with no antigenic similarity.
Failure modes
Quitting too early — the trial benefit typically appears at 8–12 weeks, not at week 2. Under-dosing — the consumer "1 g/day for joint health" label is below the dose at which trials see effect. Expecting it to replace exercise, weight management, or NSAIDs for severe OA — it sits alongside, not in place of, those interventions. Buying low-purity product from unaudited suppliers (heavy-metal and process-residue contamination is real in unbranded MSM; OptiMSM and other audited grades are the safe default).
Alternatives
For OA joint pain: glucosamine + chondroitin (similar effect magnitude, similar evidence quality, can stack with MSM per Usha and Naidu 2004); curcumin/turmeric extracts (similar small-RCT signal); omega-3 fish oil at 2–3 g/day; collagen peptides (10 g/day, growing evidence). For exercise recovery: tart cherry juice, curcumin, omega-3. None of these is a substitute for the load-bearing interventions: structured strengthening exercise, weight loss in overweight patients, and topical or oral NSAIDs at flare — which are what the OA guidelines actually recommend Bannuru et al. 2019.
Practicalities
Cost: at 3 g/day, a year's supply runs roughly $15–30 in bulk powder form from audited brands, slightly more for capsules. Available over-the-counter at pharmacies, supplement stores, and online. Crystalline powder dissolves in water with a faintly bitter taste; capsules avoid the taste. Look for purified-grade MSM (OptiMSM or equivalent COA-backed product); unbranded bulk MSM can carry process residues. No prescription, no monitoring required.
Stakes and payoff
The honest framing: a cheap, very safe symptomatic adjunct with modest evidence — best evidence in knee OA, secondary evidence in exercise recovery, weakest in skin/hair/nails. Stakes if ignored are essentially "you'd be relying on the next-best intervention" rather than missing a transformative outcome. Payoff if it works: meaningful but not dramatic — a few WOMAC points off knee pain, slightly easier stairs, faster bounce-back from a hard training week. Onset latency 8–12 weeks for joint endpoints; 2–4 weeks for muscle recovery.
Credibility range
The optimist case
Five small RCTs in knee OA all point the same direction; the systematic review confirms a consistent positive signal even though it stops short of "definitive" Brien et al. 2008. The mechanism — sulfur donation to glutathione and matrix sulfation, NF-κB suppression — is biologically reasonable and matches the magnitude of effect seen. The safety profile is among the cleanest of any supplement (LD50 exceeds table salt; no serious AEs in trials up to 6 g/day for months). The cost is trivial. The downside of a 12-week trial of MSM at 3 g/day is essentially zero. Standard-of-care OA management is itself only modestly effective; adding a safe, cheap, evidence-supported adjunct is reasonable. The "guidelines don't mention it" objection is partly because guideline panels weight large RCTs heavily and the MSM trial portfolio is consistent but small — absence from a guideline is not refutation.
The skeptic case
All five OA RCTs are small (n=22–118), short (≤12 weeks), and several were industry-supported. No multi-centre, long-duration, structure-modifying trial exists. Effect sizes are modest (a few WOMAC points) and within the range where placebo response in OA trials reliably operates. The "anti-inflammatory" claim rests on cell-culture work and a few human CRP changes of unclear clinical meaning. No major guideline (OARSI, ACR, AAOS, NICE) endorses MSM, which would not be the case if the evidence were robust Bannuru et al. 2019. Skin/hair/nail benefits are speculative — the trial work uses combination products and subjective outcomes. The supplement industry pushes MSM hard because its margins are good and its safety is unimpeachable, but "safe and cheap" is not the same as "works." A reasonable Bayesian prior on "modest effect in OA, real but small" is appropriate; anything stronger is overreach.
The author's call
Real but modest. The OA evidence is the load-bearing leg and it holds — multiple small RCTs in the same direction, plausible mechanism, exceptional safety. The skin/hair/nail evidence is too thin to dwell on but mechanism-plausible enough to score lightly. The right meta posture: evidence 2 (small RCTs, consistent direction, no large trial), controversy 1 (it is not a battleground; mainstream rheumatology is uninterested rather than opposed), health_short_term 2 (modest but real improvement in joint symptoms for the right patient), beauty_cumulative 2 (sulfur is genuinely a substrate, supplementation effect is modest), beauty_direct 1 (skin-tone evidence too thin to claim more). Best framed in the article as "cheap, safe, mild help for knee pain; everything else is bonus, not promise."
Stakeholder and incentive map
- Supplement makers — Bergstrom Nutrition (OptiMSM brand) funds much of the human research and supplies most clinical-trial material. Strong commercial incentive to promote; also the most rigorous-quality source of bulk material.
- Integrative medicine and chiropractic — frequent recommenders of MSM as part of joint-support stacks. Sometimes overpromise the "cartilage rebuild" claim.
- Orthopaedic surgeons and rheumatologists — largely indifferent; not in guidelines, so not in routine practice. Few are opposed; most simply don't engage.
- Athletes and physical therapists — informal endorsement around muscle recovery, mostly via word of mouth and one trial.
- Veterinary use — MSM is widely used in equine joint products; the veterinary literature has fed crossover claims to the human market.
Population variability
Mild-to-moderate knee OA is where the trial signal is strongest; severe end-stage OA needs structural intervention and MSM is unlikely to help meaningfully. Athletes and weekend trainers may see recovery benefit; sedentary readers without joint complaints have little to gain. Older adults (60+) are the prevalence-weighted target. Pregnancy, breastfeeding, and anti-coagulated patients should defer to a clinician on theoretical grounds. Vegan and very low-protein diets may have a lower baseline sulfur availability and theoretically benefit more, but no trial has stratified by baseline sulfur status. Hair, skin, and nail effects are most plausible in people with marginal protein or sulfur intake; there is no evidence of dose-response in well-nourished healthy adults.
Knowledge gaps
No large multi-centre RCT with structural endpoints (cartilage MRI, joint-space narrowing) exists; this is the trial that would either elevate MSM to guideline status or definitively limit it to symptomatic management. Long-term (>12 month) safety data in humans is thin — practical experience and animal data support safety, but trial data does not extend beyond about 6 months. The skin/hair/nail claims need monotherapy trials with objective endpoints; current data is combination-product and subjective. Whether baseline sulfur status predicts response is unknown — a deficiency-stratified trial could explain the variable response that practitioners describe. Mechanism evidence is largely in vitro; in vivo human evidence for NF-κB suppression or matrix-sulfation effects is inferential.
Scope and narrowing
The brief named joint pain, inflammation, skin, hair, and nails. The article covers all five but unevenly, in proportion to the evidence: knee osteoarthritis pain and exercise recovery carry the main weight (best trial backing); skin, hair, and nails are addressed honestly in a single audience section that names the marketing-vs-evidence gap rather than pretending the evidence is stronger than it is. Allergic rhinitis (which MSM is occasionally marketed for) was deliberately excluded — single open-label industry-funded trial, not worth the words.
Rating difficulties
- health_short_term at 2. Considered 3. Four placebo-controlled RCTs converge on roughly a 25–30% pain reduction at 8–12 weeks, which sounds like a "clear functional improvement" (the §5c anchor for 3). Held at 2 because the trials are small (n=22–118), the effect on absolute pain points is modest, and no guideline endorses it. The "clear, named effect" anchor for 3 felt over-claimed.
- beauty_cumulative at 2. Mechanism (sulfur substrate for keratin and collagen) is real; trial data is thin and combination-product. Score 2 ("real but small contribution over months/years") is honest; 3 would overclaim what the evidence supports.
- evidence at 2. The temptation was 3 because five RCTs all point the same way, but the trials are individually small and a major guideline (OARSI 2019) does not include MSM. Score 2 ("sparse or contested literature; mechanism plausible but trials thin or mixed") is the right anchor.
- controversy at 1. Not because there's no disagreement — guidelines vs. integrative practice diverge — but because nobody is fighting about it. Mainstream rheumatology's posture is indifference, not opposition.
Hard calls during the write
- Wrote the dream narrative even at sub-40 overall (~15), in the relief / not-being-conned lever. The catalogue has a real editorial use for the "you're paying for snake oil; here's the cheap honest thing instead" hook on supplement entries, and the dek and tagline carry it without overclaiming.
- Kept the felt-experience framing modest. The temptation on a supplement entry is to write payoff in the same register as a sleep or exercise entry; here the payoff is genuinely small and the prose has to match. Anything punchier would ring false.
- Mentioned OptiMSM by brand name in protocol and failure-modes. Not a sponsorship signal — it is in fact the brand most clinical trials have used, and the audited-grade-vs-bulk-residue point is a real safety consideration that warrants a brand pointer.
Future link candidates
- Glucosamine and chondroitin — natural co-entry, stacks with MSM per Usha 2004; should cross-link when written.
- Curcumin / turmeric — sibling supplement with similar evidence profile.
- Collagen peptides — referenced here for the hair/skin/nail case where MSM is weak; deserves its own entry.
- Knee osteoarthritis (condition) — would be the load-bearing parent entry for MSM, exercise, weight loss, NSAIDs, glucosamine; doesn't yet exist.
- Sulfa allergy myth — could become a small misconception entry if other supplements run into the same confusion.
Separate-entry candidates
- DMSO (dimethyl sulfoxide). Touched on in the
misconceptionssection to distinguish from MSM. Has its own controversial history as a topical analgesic and industrial solvent; warrants a standalone entry, not a subsection here. - Knee osteoarthritis non-surgical management. Mentioned in
alternatives; the OARSI guideline summary deserves its own catalogue entry.
MSM (Methylsulfonylmethane)
Roughly $15–30/year at 3 g/day in bulk audited-grade powder; capsules slightly more. Trivial relative to almost every other catalogue intervention.
A daily scoop in water or two capsules — a few seconds. The only friction is remembering to take it for the 8–12 weeks needed before judging joint effect.
Real mechanism — sulfur is structurally required for keratin disulfide bonds and collagen cross-linking (Butawan et al. 2017) — but supplementation effect over months in well-nourished adults is small and only documented in combination products and subjective endpoints. Score 2: real-but-small long-term contribution.
Four small placebo-controlled RCTs in knee OA (Kim et al. 2006; Usha and Naidu 2004; Debbi et al. 2011; Lubis et al. 2017) converge on roughly 25–30% VAS pain and WOMAC function reduction at 8–12 weeks. Modest but real symptomatic improvement for the right patient. The systematic review (Brien et al. 2008) calls the signal positive but not definitive.
Five small RCTs in knee OA (n=22–118, ≤12 weeks) consistent in direction; one systematic review (Brien et al. 2008) calls the signal positive but not definitive. No major guideline (OARSI 2019, ACR, AAOS) endorses MSM (Bannuru et al. 2019). Skin/hair/nail RCTs are smaller, combination-product, subjective-endpoint. Score 2 fits: sparse-to-emerging literature, mechanism plausible, no Cochrane-level synthesis.
Direct topical-tier skin effects are not credibly established. The Berardesca rosacea trial used silymarin + MSM so monotherapy effect is unidentifiable (Berardesca et al. 2008). No short-term visible facial transformation evidence; the 1 reflects a plausible-but-thin substrate role.